LONDON (Alliance News) - Scancell Holdings PLC Tuesday said its patent application for Moditope has been published, with a view to guarding the platform until 2033 once the patent is granted.
In a statement, Scancell said the application for the Modicope platform describes how it uses certain cells to get rid of tumours.
Scancell, which develops immunotherapies to treat cancer, said planning is underway for the manufacture, preclinical testing and first-in-man clinical development of the Modi-1, the first Moditope immunotherapeutic.
"The publication of the patent application is another important milestone in the development of a range of novel immunotherapeutics from the Moditope platform," Lindy Durrant, Professor of Cancer Immunotherapy at the University of Nottingham and Joint Chief Executive of ScancellRecent, said in a statement.
"Recent data suggest that Modi-1 may exhibit potent anti-tumour effects even against established aggressive tumours, dramatically improving survival rates. We look forward to a busy and exciting year in which we continue to prepare Modi-1 for clinical trials which are on schedule to start in early 2016," Durrant added.
Scancell shares were Tuesday quoted at 34.05 pence, up 0.55 pence, or 1.6%.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Scancell Holdings (SCLP)